Dynavax Technologies (DVAX) Return on Equity ROE from the third quarter 2025 to third quarter 2024 and annually, average high and low, overall ranking from Sep 30 2025 to Sep 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Dynavax Technologies Corporation  (NASDAQ: DVAX)

Dynavax Technologies's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Dynavax Technologies in the third quarter 2025?
Dynavax Technologies Corporation recorded a cumulative net loss of $-43 million during 12 months ending in the third quarter 2025, resulting in a negative return on equity (ROE) of -8.05%.

Within the Major Pharmaceutical Preparations industry 71 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2025 from 1766 to 2460.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter
Y / Y Equity Change -21.61 % -23.13 % -14.15 % -4.06 % -
Y / Y Net Income Change 53.05 % 64.42 % - 3119.18 % 23.1 %
Net Income (TTM) in Millions -43 -53 -60 27 20
Return On Equity (TTM) -8.05 % -9.16 % -9.8 % 4.3 % 3.19 %
DVAX's Total Ranking # 2460 # 1766 # 2447 # 931 # 1894
Equity (TTM) in Millions 534 494 531 597 681
Seq. Equity Change 8.09 % -6.93 % -11.04 % -12.42 % 6 %
Seq. Net Income Change 43.83 % - - -59.93 % 54.52 %

Back to DVAX Management Effectiveness >> DVAX's 5 Years Annual ROE >> Compare DVAX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 72
Sector # 216
Overall # 2460

Return On Equity Statistics
High Average Low
91.34 %
-92.83 %
-737.44 %
(Jun 30 2022)   (Mar 31 2020)





DVAX Annual Return On Equity (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Equity in Millions 597 622 581 222 59
Y / Y Equity Change -4.06 % 7.07 % 161.28 % 278.88 % 608 %
Net Income in Millions 27 -6 293 72 -75
Y / Y Net Income Change - - 305.96 % - -
Return On Equity 4.58 % -1.03 % 50.41 % 32.44 % -128.19 %

Back to DVAX Management Effectiveness >> DVAX's 5 Years Annual ROE >> Compare DVAX ROE to its Competitors




Annual Roe Comment
In 2024 ROE improved to 4.58 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
DVAX's' Return on Equity at Yahoo Finance
DVAX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for DVAX's Competitors
Subscribers only: Roe for Dynavax Technologies's Suppliers
Subscribers only: Return On Equity for DVAX's Customers




Companies with similar Return On Equity at Sep 30 2025, within Healthcare Sector ROE

Date modified: 2026-09-26T07:02:50+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.